Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
Rezdiffra's biggest growth opportunity may still be ahead.
Overview
For Madrigal Pharmaceuticals (NASDAQ: MDGL) stock to take off, three things need to happen: Sales of Rezdiffra need to keep growing; the drug needs to expand to patients with cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH); and Madrigal needs to prove it has something valuable beyond it.
Rezdiffra is Madrigal's once-daily pill for MASH, a serious liver disease caused by a buildup of fat that can lead to inflammation, liver scarring, and eventually liver failure or liver cancer. Rezdiffra is currently approved for patients with moderate-to-advanced liver scarring, but not cirrhosis.
Details
That's where the second opportunity comes in. MASH cirrhosis is essentially the next, more advanced stage of the disease, when the liver has become severely scarred. Madrigal estimates there are roughly 245,000 diagnosed patients with MASH cirrhosis in the U.S. under specialist care, and there are currently no approved drugs specifically for them.
Source
Originally published at www.fool.com.